These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

603 related items for PubMed ID: 10573115

  • 1. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G, D'Aiuto G, Comella P, Apicella A, Thomas R, Capasso I, Di Bonito M, Cartenì G, Biglietto M, De Lucia L, Maiorino L, Piccolo S, Bianchi U, D'Aniello R, Lapenta L, Comella G.
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
    Frasci G, D'Aiuto G, Comella P, Thomas R, Capasso I, Di Bonito M, Rivellini F, Carteni G, De Lucia L, Maiorino L, D'Aniello R, Frezza P, Lapenta L, Comella G.
    Breast Cancer Res Treat; 2000 Jul; 62(2):87-97. PubMed ID: 11016746
    [Abstract] [Full Text] [Related]

  • 3. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
    Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R, Capasso I, Casaretti R, Daponte A, Caponigro F, Gravina A, Maiorino L, Caratení G, Gentile A, Comella G.
    Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
    [Abstract] [Full Text] [Related]

  • 4. Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study.
    Frasci G, Comella P, Carreca I, DeCataldis G, Muci D, Brunetti C, Russo A, Palmeri S, D'Aniello R, Giordano R, D'Aiuto M, Comella G, Southern Italy Cooperative Oncology Group.
    Oncology; 2005 May; 68(2-3):223-9. PubMed ID: 16015038
    [Abstract] [Full Text] [Related]

  • 5. Cisplatin-paclitaxel weekly schedule in advanced solid tumors: a phase I study.
    Frasci G, Comella P, Parziale A, Casaretti R, Daponte A, Gravina A, De Rosa L, Gallipoli A, Comella G.
    Ann Oncol; 1997 Mar; 8(3):291-3. PubMed ID: 9137800
    [Abstract] [Full Text] [Related]

  • 6. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.
    Frasci G, Panza N, Comella P, Cartení G, Guida T, Nicolella GP, Natale M, Lombardi R, Apicella A, Pacilio C, Gravina A, Lapenta L, Comella G.
    Ann Oncol; 1999 Mar; 10(3):355-8. PubMed ID: 10355583
    [Abstract] [Full Text] [Related]

  • 7. A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study.
    Frasci G, D'Aiuto G, Comella P, Thomas R, Botti G, Di Bonito M, D'Aiuto M, Romano G, Rubulotta MR, Comella G.
    Ann Oncol; 2005 Aug; 16(8):1268-75. PubMed ID: 15937055
    [Abstract] [Full Text] [Related]

  • 8. Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study.
    Gebbia V, Di Marco P, Borsellino N, Gebbia N, Valerio MR, Fallica G, Tirrito ML, Valenza R, Citarrella P, Benedetti Panici P.
    Anticancer Drugs; 2003 Jun; 14(5):359-64. PubMed ID: 12782942
    [Abstract] [Full Text] [Related]

  • 9. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
    Pietri E, Andreis D, Fabbri F, Menna C, Schirone A, Kopf B, Rocca A, Amadori D, De Giorgi U.
    Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
    [Abstract] [Full Text] [Related]

  • 10. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
    Frasci G, Comella P, Scoppa G, Guida C, Gravina A, Fiore F, Casaretti R, Daponte A, Parziale A, Comella G.
    J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
    [Abstract] [Full Text] [Related]

  • 11. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
    Iaffaioli RV, Tortoriello A, Santangelo M, Turitto G, Libutti M, Benassai G, Frattolillo A, Ciccarelli PD, De Rosa P, Crovella F, Carbone I, Barbarisi A.
    Clin Oncol (R Coll Radiol); 2000 Apr; 12(4):251-5. PubMed ID: 11005695
    [Abstract] [Full Text] [Related]

  • 12. Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
    Frasci G, D'Aiuto G, Comella P, Thomas R, Botti G, Di Bonito M, De Rosa V, Iodice G, Rubulotta MR, Comella G, Southern Italy Cooperative Oncology Group (SICOG).
    Br J Cancer; 2006 Oct 23; 95(8):1005-12. PubMed ID: 17047649
    [Abstract] [Full Text] [Related]

  • 13. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R, Hornedo J, Colomer R, Mendiola C, Brandariz A, Sevilla E, Alvarez-Vicent J, Cortés-Funes H.
    Semin Oncol; 1995 Dec 23; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [Abstract] [Full Text] [Related]

  • 14. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).
    Kouroussis C, Xydakis E, Potamianou A, Giannakakis T, Kakolyris S, Agelaki S, Sara E, Malamos N, Alexopoulos A, Mavroudis D, Samonis G, Papadouris S, Georgoulias V, Panagos G.
    Ann Oncol; 1999 May 23; 10(5):547-52. PubMed ID: 10416004
    [Abstract] [Full Text] [Related]

  • 15. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
    Jary M, Ghiringhelli F, Jacquin M, Fein F, Nguyen T, Cleau D, Nerich V, El Gani M, Mathieu P, Valmary-Degano S, Arnould L, Lassabe C, Lamfichekh N, Fratté S, Paget-Bailly S, Bonnetain F, Borg C, Kim S.
    Cancer Chemother Pharmacol; 2014 Jul 23; 74(1):141-50. PubMed ID: 24824852
    [Abstract] [Full Text] [Related]

  • 16. Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer.
    Mantovani G, Macciò A, Lai P, Massa E, Massa D, Mulas C, Succu G, Mudu MC, Manca G, Versace R, Pisano A.
    J Immunother; 2000 Jul 23; 23(2):267-74. PubMed ID: 10746553
    [Abstract] [Full Text] [Related]

  • 17. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U, Wilke H, Seeber S.
    Semin Oncol; 1996 Oct 23; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [Abstract] [Full Text] [Related]

  • 18. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF, Michelotti A, Baldini E, Salvadori B, Gennari A, Da Prato M, Tibaldi C, Salzano E, Gentile A.
    Semin Oncol; 1996 Oct 23; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [Abstract] [Full Text] [Related]

  • 19. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A, Salzano E.
    Semin Oncol; 1996 Oct 23; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [Abstract] [Full Text] [Related]

  • 20. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
    Frasci G, Panza N, Comella P, Nicolella GP, Natale M, Manzione L, Bilancia D, Cioffi R, Maiorino L, De Cataldis G, Belli M, Micillo E, Mascia V, Massidda B, Lorusso V, De Lena M, Carpagnano F, Contu A, Pusceddu G, Comella G.
    J Clin Oncol; 1999 Aug 23; 17(8):2316-25. PubMed ID: 10561293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.